Akers Biosciences, Inc., together with its subsidiaries, develops, produces, and sells rapid screening and testing products designed to deliver medical devices to healthcare providers and consumers in the United States, the People’s Republic of China, and internationally.
The last earnings update was 37 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Akers Biosciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Akers Biosciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Akers Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Akers Biosciences's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Akers Biosciences's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Akers Biosciences's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Akers Biosciences is high growth as no earnings estimate data is available.
Unable to determine if Akers Biosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Akers Biosciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Akers Biosciences's finances.
The net worth of a company is the difference between its assets and liabilities.
Akers Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Akers Biosciences has no long term commitments.
This treemap shows a more detailed breakdown of
Akers Biosciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Akers Biosciences has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Howard R. Yeaton, Jr., CPA, has been the Chief Executive Officer of Akers Biosciences Inc., since October 05, 2018. Mr. Yeaton has been an Interim Chief Financial Officer at Akers Biosciences, Inc. since October 5, 2018. Mr. Yeaton an Interim Chief Financial Officer of Propel Media, Inc. since 2014. Mr. Yeaton is the Founder and Managing Principal, since 2003, of Financial Consulting Strategies LLC. He has been the Managing Principal of Financial Consulting Strategies LLC since 2003. Mr. Yeaton served as an Interim Chief Financial Officer of Energous Corporation from July 14, 2014 to July 13, 2015. Mr. Yeaton served as Interim Chief Financial Officer at Kitara Media Corp. since October 14, 2014. He served in various financial leadership positions for Konica and Teco Energy. He began his career with Deloitte, an international accounting and auditing firm. Mr. Yeaton served in various leadership positions for an international public consumer products corporation. He has been Vice Chairman of Stewardship Financial Corp. since May 2015. He has been the Vice Chairman of Atlantic Stewardship Bank, Inc. since May 2015. He serves as a Director of Atlantic Stewardship Bank's Bergen County Business Development Board. He has been Independent Director of Stewardship Financial Corp. and its subsidiary Atlantic Stewardship Bank, Inc. since 2005. He is a Member of the Financial Executives Institute and the American Institute of CPAs. He holds an MBA from the University of Connecticut and a BS in Accounting from Florida State University.
Insufficient data for Howard to compare compensation growth.
Howard's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Akers Biosciences management team is less than 2 years, this suggests a new team.
CEO & Interim CFO
Senior Vice President of Global Marketing & Commercial Operations
Vice President of Sales & Distribution
VP of Finance & Treasurer
Board of Directors
Chairman of Scientific Advisory Board
Co-Independent Lead Director
Co-Independent Lead Director
Who owns this company?
Recent Insider Trading
No 3 month individual insider trading information.
Akers Biosciences, Inc., together with its subsidiaries, develops, produces, and sells rapid screening and testing products designed to deliver medical devices to healthcare providers and consumers in the United States, the People’s Republic of China, and internationally. Its products include BreathScan, a disposable breath alcohol detector; PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol ‘Check’, a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek that detects aldehydes or oxidative stress in exhaled human breath. The company was founded in 1989 and is headquartered in Thorofare, New Jersey.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.